Hint mode is switched on Switch off
For swift navigation between sections

Organization: Bristol Myers Squibb
LEI HLYYNH7UQUORYSJQCN42, SWIFT BMYPUS33XXX

Organization name
Bristol-Myers Squibb Company
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
42,734 mln USD

Find Any Data on Any Bond in Just One Click

Full data on over 500,000 bonds and stocks worldwide

Powerful bond screener

Ratings from the top 3 global ratings agencies, plus over 70 local ones

Over 300 pricing sources from the OTC market and world stock exchanges

User-friendly and intuitive across multiple platforms

Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.

Awards

News

09/08/2023 Bristol Myers Squibb: Other Events
14/06/2023 S&P Global Ratings affirms Bristol Myers Squibb at "A+" (Foreign Currency LT credit rating); outlook stable
14/06/2023 S&P Global Ratings affirms Bristol Myers Squibb at "A+" (Local Currency LT credit rating); outlook stable
02/05/2023 Bristol Myers Squibb: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Submission Of Matters To A Vote Of Security Holders
27/04/2023 Bristol Myers Squibb Reports First Quarter Financial Results for 2023
All organization news

Documentation

IFRS/US GAAP reports

2023
I q eng
II q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Bond debt by currency

Show more Hide

Codes

  • LEI
    HLYYNH7UQUORYSJQCN42
  • SWIFT
    BMYPUS33XXX
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • ICB
    4,500 Health Care
  • CIK
    0000014272

Credit ratings

Macroeconomic Indicators - Bristol Myers Squibb

Registration is required to get access.